Zhao Yanchun, Du Jingfang, Zhuo Jian, Zhang Quanai, Dai Luxian, Tang Yubao, Wang Yao, Sheng Ankang, Yao Hanyu, Liu Weiguang
Department of Outpatient, Affiliated Hospital of Hebei University of Engineering, Handan, 056000, Hebei, China.
School of Clinical Medicine, The Hebei University of Engineering, Handan, 056000, Hebei, China.
Clin Exp Med. 2024 Dec 21;25(1):23. doi: 10.1007/s10238-024-01522-w.
Liver hepatocellular carcinoma (LIHC) is a malignancy characterized by a high rate of recurrence, metastasis, and poor prognosis. Cytochrome b561 (CYB561) has been previously reported to be associated with tumor progression, but it has not been revealed in LIHC. The aim of this study was to investigate the prognostic value and potential function of CYB561 in LICH. The expression level, clinical correlation, prognosis, and biological function of CYB561 in LIHC were analyzed using The Cancer Genome Atlas（TCGA), Gene Expression Omnibus (GEO), TIMER2, Kaplan-Meier Plotter, and GEPIA2 databases. The expression of CYB561 in LIHC tissue samples was analyzed by immunohistochemical staining. The effect of CYB561 on the proliferation and migration of LIHC cells was investigated by using CYB561 knockdown in vitro. GSE149614 dataset was used to analyze the expression distribution of CYB561 in LIHC on a single-cell dimension. This study showed that CYB561 mRNA and protein were highly expressed in LIHC. High expression of CYB561 suggests poor prognosis in LICH patients and is an independent risk factor for LIHC. Wound-healing experiment, transwell experiment, and clonal formation experiment confirmed that CYB561 knockdown could inhibit the proliferation and migration of LIHC cells. Functional enrichment analysis showed that CYB561 was related to biological processes such as cell adhesion and immune response. KEGG enrichment analysis showed that CYB561 interacts with tumor-related signaling pathways. Single-cell analysis showed that CYB561 was mainly expressed in hepatocytes. Cells with high CYB561 expression had a higher degree of malignancy. Our study found that abnormal expression of CYB561 in LIHC suggested poor prognosis of LIHC and was related to tumor migration and proliferation. CYB561 is a potential prognostic predictor or therapeutic biomarker.
肝细胞癌（LIHC）是一种具有高复发率、高转移率和不良预后特征的恶性肿瘤。细胞色素b561（CYB561）此前已有报道与肿瘤进展相关，但在肝细胞癌中尚未见相关报道。本研究旨在探讨CYB561在肝细胞癌中的预后价值和潜在功能。利用癌症基因组图谱（TCGA）、基因表达综合数据库（GEO）、TIMER2、Kaplan-Meier Plotter和GEPIA2数据库分析CYB561在肝细胞癌中的表达水平、临床相关性、预后及生物学功能。通过免疫组化染色分析CYB561在肝细胞癌组织样本中的表达。利用体外敲低CYB561的方法研究其对肝细胞癌细胞增殖和迁移的影响。使用GSE149614数据集在单细胞层面分析CYB561在肝细胞癌中的表达分布。本研究表明CYB561 mRNA和蛋白在肝细胞癌中高表达。CYB561高表达提示肝细胞癌患者预后不良，是肝细胞癌的独立危险因素。伤口愈合实验、Transwell实验和克隆形成实验证实，敲低CYB561可抑制肝细胞癌细胞的增殖和迁移。功能富集分析表明CYB561与细胞黏附、免疫反应等生物学过程相关。KEGG富集分析表明CYB561与肿瘤相关信号通路相互作用。单细胞分析表明CYB561主要在肝细胞中表达。CYB561高表达的细胞具有更高的恶性程度。我们的研究发现，CYB561在肝细胞癌中的异常表达提示肝细胞癌预后不良，且与肿瘤迁移和增殖有关。CYB561是一种潜在的预后预测指标或治疗生物标志物。
